A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells

Cancer Research

Volumn 59, Issue 19, 1999, Pages 5041-5046

  Bandyopadhyay, Abhik ^a   Zhu, Yong ^a   Cibull, Michael L ^a   Bao, LiWei ^a   Chen, Changguo ^a   Sun, LuZhe ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; METASTASIS; METASTASIS INHIBITION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANIMALS; BREAST NEOPLASMS; CELL LINE; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, NUDE; MINK; NEOPLASM METASTASIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033215194     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998 [published errata: 48: 192 and 329, 1998].
2. Smart, C. R., Byrne, C., Smith, R. A., Garfinkel, L., Letton, A. H., Dodd, G. D., and Beahrs, O. H. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA Cancer J. Clin., 47: 134-149, 1997.
3. Roberts, A. B., and Sporn, M. B. The transforming growth factor-βs. In: M. B. Sporn and A. B. Roberts (eds.), Peptide Growth Factors and Their Receptors, pp. 419-472. Heidelberg: Springer-Verlag, 1991.
4. Markowitz, S. D., and Roberts, A. B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev., 7: 93-102, 1996.
5. Norgaard, P., Hougaard, S., Poulsen, H. S., and Spang-Thomsen, M. Transforming growth factor β and cancer. Cancer Treat. Rev., 21: 367-403, 1995.
6. McCune, B. K., Mullin, B. R., Flanders, K. C., Jaffurs, W. J., Mullen, L. T., and Sporn, M. B. Localization of transforming growth factor-β isotypes in lesions of the human breast. Hum. Pathol., 23: 13-20, 1992.
7. 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ., 4: 193-201, 1993.
8. Massague, J. The transforming growth factor-β family. Annu. Rev. Cell Biol., 6: 597-641, 1990.
9. Pepin, M. C., Beauchemin, M., Collins, C., Plamondon, J., and O'Connor-McCourt, M. D. Mutagenesis analysis of the membrane-proximal ligand binding site of the TGF-β receptor type III extracellular domain. FEBS Lett., 377: 368-372, 1995.
10. Wang, X. F., Lin, H. Y., Ng-Eaton, E., Downward, J., Lodish, H. F., and Weinberg, R. A. Expression cloning and characterization of the TGF-β type III receptor. Cell, 67: 797-805, 1991.
11. 1 activity in human breast cancer MCF-7 cells. J. Biol. Chem., 272: 12862-12867, 1997.
12. Lopez-Casillas, F., Wrana, J. L., and Massague, J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell, 73: 1435-1444, 1993.
13. Sun, L., and Chen, C. Expression of transforming growth factor β type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J. Biol. Chem., 272: 25367-25372, 1997.
14. Moren, A., Ichijo, H., and Miyazono, K. Molecular cloning and characterization of the human and porcine transforming growth factor-β type III receptors. Biochem. Biophys. Res. Commun., 189: 356-362, 1992.
15. Xie, W. Q., and Rothblum, L. I. Rapid, small-scale RNA isolation from tissue culture cells. Biotechniques, 11: 324, 326-327, 1991.
16. Aslakson, C. J., and Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dessemination of subpopulations of a mouse mammary tumor. Cancer Res., 52: 1399-1405, 1992.
17. Arteaga, C. L., Hurd, S. D., Winnier, A. R., Johnson, M. D., Fendly, B. M., and Forbes, J. T. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J. Clin. Invest., 92: 2569-2576, 1993.
18. Arteaga, C. L., Coffey, R. J., Jr., Dugger, T. C., McCutchen, C. M., Moses, H. L., and Lyons, R. M. Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autocrine regulation by transforming growth factor β. Cell Growth Differ., 1: 367-374, 1990.
19. 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol., 143: 381-389, 1993.
20. Welch, D. R., Fabra, A., and Nakajima, M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl. Acad. Sci. USA, 87: 7678-7682, 1990.
21. 1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate, 37: 19-29, 1998.
22. Price, J. E., Polyzos, A., Zhang, R. D., and Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res., 50: 717-721, 1990.
23. 1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell, 86: 531-542, 1996.
24. 1 transgene expression. Proc. Natl. Acad. Sci. USA, 92: 4254-4258, 1995.
25. Bottinger, E. P., Jakubczak, J. L., Haines, D. C., Bagnall, K., and Wakefield, L. M. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res., 57: 5564-5570, 1997.
26. 1 associates with disease progression in human breast cancer. Cancer Res., 52: 6949-6952, 1992.
27. 1 correlate with disease progression in human colon cancer. Cancer Epidemiol. Biomark. Prev., 4: 549-554, 1995.
28. 1 in patients with colorectal cancer: association with disease progression. Gastroenterology, 110: 375-382, 1996.
29. 1 in human bladder cancer. Cancer (Phila.), 75: 2565-2570, 1995.
30. Friess, H., Yamanaka, Y., Buchler, M., Ebert, M., Beger, H. G., Gold, L. I., and Korc, M. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology, 105: 1846-1856, 1993.
31. Morisaki, T., Katano, M., Ikubo, A., Anan, K., Nakamura, M., Nakamura, K., Sato, H., Tanaka, M., and Torisu, M. Immunosuppressive cytokines (IL-10, TGF-β) genes expression in human gastric carcinoma tissues. J. Surg. Oncol., 63: 234-239, 1996.
32. Van Belle, P., Rodeck, U., Nuamah, I., Halpern, A. C., and Elder, D. E. Melanoma-associated expression of transforming growth factor-β isoforms. Am. J. Pathol., 148: 1887-1894, 1996.
33. 1. J. Cell Biol., 118: 715-726, 1992.
34. 1 overproduction in prostate cancer effects on growth in vivo and in vitro. Mol. Endocrinol., 6: 15-25, 1992.
35. Lopez-Casillas, F., Payne, H. M., Andres, J. L., and Massague, J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell Biol., 124: 557-568, 1994.
36. Esko, J. D., Rostand, K. S., and Weinke, J. L. Tumor formation dependent on proteoglycan biosynthesis. Science (Washington DC), 241: 1092-1096, 1988.
37. Fakhrai, H., Dorigo, O., Shawler, D. L., Lin, H., Mercola, D., Black, K. L., Royston, I., and Sobol, R. E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93: 2909-2914, 1996.
38. Sosroseno, W., and Herminajeng, E. The immunoregulatory roles of transforming growth factor β. Br. J. Biomed. Sci., 52: 142-148, 1995.
39. Dunn, S. E., Ehrlich, M., Sharp, N. J., Reiss, K., Solomon, G., Hawkins, R., Baserga, R., and Barrett, J. C. A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res., 58: 3353-3361, 1998.
40. Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., Thomas, K. A., and Curiel, D. T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA, 95: 8795-8800, 1998.
41. 1 gene expression. Cancer Res., 55: 1758-1762, 1995.
42. Ohmori, T., Yang, J. L., Price, J. O., and Arteaga, C. L. Blockade of tumor cell transforming growth factor-βs enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res., 245: 350-359, 1998.